Home > PJ (current issue) > Letters | Search

PJ Online homeThe Pharmaceutical Journal
Vol 280 No 7485 p52-53
19 January 2008

This article
Reprint   Photocopy

PDF 70K, Acrobat Reader

Letters

• Industrial pharmacists (4)
• Community pharmacy
• Responsible pharmacist (2)
• Package design
• The profession (2)
• The Society (3)
• Registration (2)
• Statins
• Retirement (2)
• Onlooker
• Caption competition


Letters to the Editor

The Society

Chatham House rules (Mr A. Matalia)

Reply from Jeremy Holmes, Chief Executive and Registrar, Royal Pharmaceutical Society

Skill enhancement or income stream? (Mr P. J. Mulholland)

GPhC should pay for access to Society’s assets (Mr M. R. Hickey)

Chatham House rules

From Mr A. Matalia, MRPharmS

I understand the Royal Pharmaceutical Society had a meeting with superintendents of retail multiples during which the subject of the future professional body, the services they would like to see and level of fees were explored. I understand these meetings were held under “Chatham House rules” without minutes being taken.

Within a modern professional body, I would argue that the practice of having secret, unminuted meetings with the employers of pharmacists is incompatible with the general feelings of the membership.

The Society is a body that is supposed to represent all members, and not just employers. When it comes to issues of services, fees and the Society’s pension gap, we all have an interest.

The moral obligations to members of the Society override the morally binding obligations of Chatham House rules. In the spirit of openness, I call upon the Society to publish the contents of these meetings, ignore the secret opinions expressed and direct the superintendents to participate in the Clarke Inquiry — which is the proper forum for such topics.

A. Matalia
Coventry

 

JEREMY HOLMES, Chief Executive and Registrar, Royal Pharmaceutical Society, responds:

Mr Matalia raises a number of issues regarding our meetings with pharmacy superintendents. We meet with a wide range of members and stakeholders from individual pharmacists through to ministers and politicians during the year to discuss a wide range of issues.

Many of these meetings are held in private. This is normal business practice and allows a free and frank exchange of ideas and opinions. There is nothing “secret” or, indeed, unusual about this.

Readers will be aware of the Clarke Inquiry into a professional body for pharmacy. The Society commissioned this inquiry, and is funding it, because we believe the future professional body should have the widest possible support from across pharmacy.

We are seeking an independent view on the principles, functions and structure of that body rather than making any unilateral decisions on our own future. Through the inquiry we genuinely want to engage with others bodies and with pharmacy professionals to ensure the future professional body is what is wanted.

Once the inquiry’s remit and chairmanship were agreed by the Society’s Council, we have been an “arm’s length” commissioner. The inquiry panel was appointed by the independent chairman and the consultation process developed independently of the Society.

We believe that it is important that all pharmacists engage with the inquiry and we would encourage them to submit their ideas to the Clarke Inquiry, if they have not already done so.

The inquiry gives pharmacists the opportunity to lay out their vision of what they would like from the professional body. We want the new professional body to have support from across the profession and to be a body that pharmacists want to join.


Skill enhancement or income stream?

From Mr P. J. Mulholland, MRPharmS

When I first registered as a supplementary prescriber we were told that this was a “one-off” fee to make the annotation to the Register. This was changed last year and all SPs had to pay a “supplementary prescriber annual retention fee” of £35 in addition to the normal retention fee in order to continue practising.

The annual fee was dropped this year. However, having now completed the conversion course for independent prescribing I find myself being required to pay another £35 in order to continue practising. Had I received my practice certificate two weeks later I would have had to pay £49.

Is the Royal Pharmaceutical Society’s Council trying to discourage pharmacists from developing and enhancing their skills or are pharmacists doing so just seen as another income stream?

Peter J Mulholland
Glasgow


GPhC should pay for access to Society’s assets

From Mr M. R. Hickey, MRPharmS

I was interested to see Your Society, the new publication distributed with the PJ of 5/12 January 2008. I was particularly drawn to the box description “What is Your Society?”

It is stated that the publication “is designed to keep members abreast of developments at the Society, as its regulatory role is taken over by the General Pharmaceutical Council and it develops its professional leadership role”.

My interpretation of this is that the editor of this publication, Jeremy Holmes, views the General Pharmaceutical Council as a novel body to be created, while the Royal Pharmaceutical Society is a body which will continue in existence, a continuing body that returns to the spirit of its original remit of 1841: the leadership of pharmacists. The language and tone of the statement would imply that the Society will not be abolished and will continue to exist.

If this is the case then I have to assume that all the assets of the Society, paid for by the members over 167 years, will be retained within the Society. The Charter only allows for the distribution of assets in the event of the Society being wound up.

I trust the Society will be making these views plain to the Clarke Inquiry, and that it will point out that, should the new council require use of, or access to, any of the assets of the Society then that council will have to pay the appropriate market value.

Maurice Hickey
Aviemore Pharmacy
Inverness-shire

Send your letter to The Editor

Previous Topic (The profession)
Next Topic (Registration)

Back to Top


©The Pharmaceutical Journal